Ardelyx, Inc. vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ARDX | JNJ | |
|---|---|---|
| Market Cap | $924.31 million | $648.67 billion |
| Revenue (TTM) | $450.89 million | $97.93 billion |
| Net Income (TTM) | $-55,702,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| ARDX | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.40 |
| Price / Book | 6.20 | 7.63 |
| Price / Sales | 2.05 | 6.62 |
ARDX leads on 2 of 2 valuation factors.
Profitability
| ARDX | JNJ | |
|---|---|---|
| Net Margin | -12.35% | 21.48% |
| Return on Equity | -37.38% | 24.76% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| ARDX | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.98% |
| Payout Ratio | — | 62.18 |
ARDX and JNJ split the dividend factors evenly.
Risk & Sentiment
| ARDX | JNJ | |
|---|---|---|
| Short Interest | 0.76% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: ARDX overview, ARDX financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.